From nonalcoholic fatty liver disease to metabolic-associated fatty liver disease: Big wave or ripple?
2
조회
0
다운로드
10
인용
0
참고문헌
키워드
초록
There is some dissatisfaction with the term “nonalcoholic fatty liver disease (NAFLD),” which overemphasizes alcohol and underemphasizes the importance of metabolic risk factors in this disease. Recently, a consensus recommended “metabolic (dysfunction)-associated fatty liver disease (MAFLD)” as a more appropriate term to describe fatty liver diseases (FLD) associated with metabolic dysfunction. During the definition change from NAFLD to MAFLD, subjects with FLD and metabolic abnormalities, together with other etiologies of liver diseases such as alcohol, virus, or medication who have been excluded from the NAFLD criteria, were added to the MAFLD criteria, while subjects with FLD but without metabolic abnormality, who have been included in the NAFLD criteria, were excluded from the MAFLD criteria. This means that there is an emphasis on the metabolic dysfunction in MAFLD which may underestimate the prognostic value of hepatic steatosis itself, whereas the MAFLD criteria might better identify subjects who are at a higher risk of hepatic or cardiovascular outcomes. However, non-metabolic risk NAFLD subjects who are excluded from the MAFLD criteria are missed from the diagnosis, and their potential risk can be the cause of future diseases. Although huge controversies remain, this review focused on summarizing recent studies that compared the clinical and prognostic characteristics between subjects with NAFLD and MAFLD.
Abstract
There is some dissatisfaction with the term “nonalcoholic fatty liver disease (NAFLD),” which overemphasizes alcohol and underemphasizes the importance of metabolic risk factors in this disease. Recently, a consensus recommended “metabolic (dysfunction)-associated fatty liver disease (MAFLD)” as a more appropriate term to describe fatty liver diseases (FLD) associated with metabolic dysfunction. During the definition change from NAFLD to MAFLD, subjects with FLD and metabolic abnormalities, together with other etiologies of liver diseases such as alcohol, virus, or medication who have been excluded from the NAFLD criteria, were added to the MAFLD criteria, while subjects with FLD but without metabolic abnormality, who have been included in the NAFLD criteria, were excluded from the MAFLD criteria. This means that there is an emphasis on the metabolic dysfunction in MAFLD which may underestimate the prognostic value of hepatic steatosis itself, whereas the MAFLD criteria might better identify subjects who are at a higher risk of hepatic or cardiovascular outcomes. However, non-metabolic risk NAFLD subjects who are excluded from the MAFLD criteria are missed from the diagnosis, and their potential risk can be the cause of future diseases. Although huge controversies remain, this review focused on summarizing recent studies that compared the clinical and prognostic characteristics between subjects with NAFLD and MAFLD.
참고문헌 (40)
- Schaffner F, "Nonalcoholic fatty liver disease", Prog Liver Dis, 8, pp.283~298 (1986)
- Eslam M, "MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease", Gastroenterology, 158, pp.1999~2014.e1 (2020)
- Cotter TG, "Nonalcoholic fatty liver disease 2020: the state of the disease", Gastroenterology, 158, pp.1851~1864 (2020)
- Silvia Sookoian, "Precision medicine in nonalcoholic fatty liver disease: New therapeutic insights from genetics and systems biology", Clinical and Molecular Hepatology, 26(4), pp.461~475 (2020), 대한간학회[DOI]
- Jeong-Ju Yoo, "Recent research trends and updates on nonalcoholic fatty liver disease", Clinical and Molecular Hepatology, 25(1), pp.1~11 (2019), 대한간학회
- Chalasani N, "The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases", Hepatology, 67, pp.328~357 (2018)
- European Association for the Study of the Liver (EASL), "EASL-EASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease", J Hepatol, 64, pp.1388~1402 (2016)
- Eslam M, "A new definition for metabolic dysfunctionassociated fatty liver disease: an international expert consensus statement", J Hepatol, 73, pp.202~209 (2020)
- Sun DQ, "PNPLA3rs738409 is associated with renal glomerular and tubular injury in NAFLD patients with persistently normal ALT levels", Liver Int, 40, pp.107~119 (2020)
- Zheng KI, "Clinical utility of the MAFLD definition", J Hepatol, 74, pp.989~991 (2021)
- Huang Shang-Chin, "Clinical and Histologic Features of Patients with Biopsy-Proven Metabolic Dysfunction-Associated Fatty Liver Disease", Gut and Liver, 15(3), pp.451~458 (2021), 거트앤리버 소화기연관학회협의회[DOI]
- Ciardullo S, "Prevalence of NAFLD, MAFLD and associated advanced fibrosis in the contemporary United States population", Liver Int (2021)[DOI]
- Huang J, "MAFLD criteria overlooks a number of patients with severe steatosis: is it clinically relevant?", J Hepatol, 73, pp.1265~1267 (2020)
- Brunner KT, "Increasing liver fat is associated with progression of cardiovascular risk factors", Liver Int, 40, pp.1339~1343 (2020)
- Mantovani A, "Non-alcoholic fatty liver disease and risk of incident diabetes mellitus: an updated meta-analysis of 501 022 adult individuals", Gut (2020)[DOI]
- Lee H, "Metabolic dysfunction-associated fatty liver disease and incident cardiovascular disease risk: a nationwide cohort study", Clin Gastroenterol Hepatol (2020)[DOI]
- Sun DQ, "MAFLD and risk of CKD", Metabolism, 115, pp.154433~ (2021)
- Yamamura S, "MAFLD identifies patients with significant hepatic fibrosis better than NAFLD", Liver Int, 40, pp.3018~3030 (2020)
- Lin YC, "New perspectives on genetic prediction for pediatric metabolic associated fatty liver disease", Front Pediatr, 8, pp.603654~ (2020)
- Liu Z, "The health impact of MAFLD, a novel disease cluster of NAFLD, is amplified by the integrated effect of fatty liver disease-related genetic variants", Clin Gastroenterol Hepatol (2020)[DOI]
- Kyung-Soo Kim, "Beneficial effect of anti-diabetic drugs for nonalcoholic fatty liver disease", Clinical and Molecular Hepatology, 26(4), pp.430~443 (2020), 대한간학회[DOI]
- Lin S, "Comparison of MAFLD and NAFLD diagnostic criteria in real world", Liver Int, 40, pp.2082~2089 (2020)
- Wai-Sun Wong V, "Impact of the new definition of metabolic associated fatty liver disease on the epidemiology of the disease", Clin Gastroenterol Hepatol, pp.046~ (2020)[DOI]
- Niriella MA, "Outcomes of NAFLD and MAFLD: results from a community-based, prospective cohort study", PLoS One, 16, pp.e0245762~ (2021)
- Vahdat S, "Patient involvement in health care decision making: a review", Iran Red Crescent Med J, 16, pp.e12454~ (2014)
- Yilmaz Y, "A single-letter change in an acronym:signals, reasons, promises, challenges, and steps ahead for moving from NAFLD to MAFLD", Expert Rev Gastroenterol Hepatol (2020)[DOI]
- Wong VW, "Asia-Pacific working party on non-alcoholic fatty liver disease guidelines 2017-part 1: definition, risk factors and assessment", J Gastroenterol Hepatol, 33, pp.70~85 (2018)
- Chang Y, "Nonheavy drinking and worsening of noninvasive fibrosis markers in nonalcoholic fatty liver disease: a cohort study", Hepatology, 69, pp.64~75 (2019)
- Liu B, "Body mass index and risk of liver cirrhosis in middle aged UK women: prospective study", BMJ, 340, pp.c912~ (2010)
- Robinson P, "Measuring attitudes towards mental health using social media: investigating stigma and trivialisation", Soc Psychiatry Psychiatr Epidemiol, 54, pp.51~58 (2019)
- Cleveland ER, "Low awareness of nonalcoholic fatty liver disease in a populationbased cohort sample: the CARDIA study", J Gen Intern Med, 34, pp.2772~2778 (2019)
- Singh A, "Awareness of nonalcoholic fatty liver disease is increasing but remains very low in a representative US cohort", Dig Dis Sci, 65, pp.978~986 (2020)
- Wieland AC, "Low awareness of nonalcoholic fatty liver disease among patients at high metabolic risk", J Clin Gastroenterol, 49, pp.e6~e10 (2015)
- Alem SA, "Capturing patient experience: a qualitative study of change from NAFLD to MAFLD real-time feedback", J Hepatol (2021)[DOI]
- Fouad Y, "Change from NAFLD to MAFLD increases the awareness of fatty liver disease in primary care physicians and specialists", J Hepatol (2021)[DOI]
- Shiha G, "Redefining fatty liver disease: an international patient perspective", Lancet Gastroenterol Hepatol, 6, pp.73~79 (2021)
- Zheng KI, "From NAFLD to MAFLD: a “redefining” moment for fatty liver disease", Chin Med J (Engl), 133, pp.2271~2273 (2020)
- Younossi ZM, "From NAFLD to MAFLD: implications of a premature change in terminology", Hepatology, 73, pp.1194~1198 (2021)
- Singh SP, "Non-alcoholic fatty liver disease: not time for an obituary just yet!", J Hepatol, 74, pp.972~974 (2021)
- Lee GH, "Validation of genetic variants associated with metabolic dysfunction-associated fatty liver disease in an ethnic Chinese population", World J Hepatol, 12, pp.1228~1238 (2020)